OKYO Pharma (OKYO) Change in Accured Expenses (2023 - 2025)

OKYO Pharma (OKYO) has 3 years of Change in Accured Expenses data on file, last reported at $8.1 million in Q3 2025.

• Change in Accured Expenses for Q3 2025 came in at $8.1 million, down 19.85% year-over-year; the trailing twelve-month figure through Sep 2025 was $8.1 million (down 19.85% YoY), and the FY2025 annual result was $9.2 million, up 24.34% from the prior year.
• Change in Accured Expenses slipped to $8.1 million in Q3 2025 per OKYO's latest filing, from $9.2 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $10.1 million in Q3 2024 and troughed at $7.4 million in Q1 2024.
• A 3-year average of $8.6 million and a median of $8.3 million in 2023 frame the typical range for Change in Accured Expenses.
• On a YoY basis, Change in Accured Expenses climbed as much as 24.34% in 2025 and fell as far as 19.85% in 2025.
• A 3-year view of Change in Accured Expenses shows it stood at $8.3 million in 2023, then advanced by 20.91% to $10.1 million in 2024, then slipped by 19.85% to $8.1 million in 2025.
• Business Quant data shows OKYO's Change in Accured Expenses at $8.1 million in Q3 2025, $9.2 million in Q1 2025, and $10.1 million in Q3 2024.